KR100532178B1 - 인간화 항-ＣＤ11ａ 항체 - Google Patents

인간화 항-ＣＤ11ａ 항체 Download PDF

Info

Publication number
KR100532178B1
KR100532178B1 KR10-1999-7004671A KR19997004671A KR100532178B1 KR 100532178 B1 KR100532178 B1 KR 100532178B1 KR 19997004671 A KR19997004671 A KR 19997004671A KR 100532178 B1 KR100532178 B1 KR 100532178B1
Authority
KR
South Korea
Prior art keywords
antibody
delete delete
cd11a
humanized anti
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-1999-7004671A
Other languages
English (en)
Korean (ko)
Other versions
KR20000069147A (ko
Inventor
파울라 엠. 자르듀
레오나르드 지. 프레스타
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20000069147A publication Critical patent/KR20000069147A/ko
Application granted granted Critical
Publication of KR100532178B1 publication Critical patent/KR100532178B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR10-1999-7004671A 1996-11-27 1997-10-20 인간화 항-ＣＤ11ａ 항체 Expired - Lifetime KR100532178B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
US8/757,205 1996-11-27
US08/757,205 1996-11-27
PCT/US1997/019041 WO1998023761A1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Publications (2)

Publication Number Publication Date
KR20000069147A KR20000069147A (ko) 2000-11-25
KR100532178B1 true KR100532178B1 (ko) 2005-12-01

Family

ID=25046834

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7004671A Expired - Lifetime KR100532178B1 (ko) 1996-11-27 1997-10-20 인간화 항-ＣＤ11ａ 항체

Country Status (17)

Country Link
EP (2) EP1516629B1 (https=)
JP (2) JP3778945B2 (https=)
KR (1) KR100532178B1 (https=)
AR (1) AR008919A1 (https=)
AT (1) ATE267257T1 (https=)
AU (1) AU731817C (https=)
CA (1) CA2272842C (https=)
DE (3) DE122004000047I1 (https=)
DK (2) DK1516629T3 (https=)
ES (1) ES2221045T3 (https=)
FR (1) FR04C0028I2 (https=)
IL (3) IL130143A0 (https=)
LU (1) LU91122I2 (https=)
NL (1) NL300163I2 (https=)
PT (1) PT941344E (https=)
WO (1) WO1998023761A1 (https=)
ZA (1) ZA979599B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
IL145480A0 (en) * 1999-03-19 2002-06-30 Genentech Inc Treatment of lfa-1 associated disorders with increasing doses of lfa-1
DE60039783D1 (de) * 1999-12-14 2008-09-18 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
AU2001287000A1 (en) * 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
KR100872210B1 (ko) * 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
JP5054385B2 (ja) 2004-02-19 2012-10-24 ダイアックス、コープ 立体配座特異的抗体
AU2005254980A1 (en) * 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
MX2011001506A (es) 2008-08-14 2011-03-15 Genentech Inc Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
BRPI0918978A2 (pt) 2008-09-10 2015-12-01 Genentech Inc composições e métodos a prevenção da degradação oxidativa das proteínas
CN102257122B (zh) 2008-12-16 2015-07-29 Emd密理博公司 搅拌槽反应器及方法
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
JP2013510577A (ja) 2009-11-12 2013-03-28 ブイビーアイ テクノロジーズ， エルエルシー 胞子様細胞の亜集団およびその用途
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN104998269B (zh) 2010-03-22 2019-06-11 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
CN107312062B (zh) 2010-05-17 2021-03-16 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
AU2013240280A1 (en) 2012-03-27 2014-10-16 Genentech, Inc. Improved harvest operations for recombinant proteins
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
BR112017000142B1 (pt) 2014-07-09 2021-08-17 Genentech, Inc Métodos para melhorar a recuperação por descongelamento de bancos de células e para congelamento de células cho para armazenamento, grupo de células cho para o congelamento de células de mamíferos, e banco de células
HUE070383T2 (hu) 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
SG11201808562SA (en) 2016-03-29 2018-10-30 Geltor Inc Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
MX2019007433A (es) 2016-12-22 2019-08-16 Genentech Inc Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
EP3818078B1 (en) 2018-07-03 2024-02-28 Bristol-Myers Squibb Company Methods of producing recombinant proteins
US12415980B2 (en) 2018-10-10 2025-09-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
BR112021019612A2 (pt) 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
KR20210151930A (ko) 2019-04-12 2021-12-14 젤터, 인코포레이티드 재조합 엘라스틴 및 이의 제조
JP2022543781A (ja) 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
JP7808097B2 (ja) 2020-09-22 2026-01-28 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
DE69729209D1 (de) 2004-06-24
EP1516629A2 (en) 2005-03-23
DK0941344T3 (da) 2004-09-27
EP1516629B1 (en) 2013-04-03
DE122004000047I2 (de) 2006-06-14
AR008919A1 (es) 2000-02-23
NL300163I2 (nl) 2005-07-01
AU731817B2 (en) 2001-04-05
IL175583A0 (en) 2006-09-05
EP1516629A3 (en) 2006-09-27
FR04C0028I1 (https=) 2005-02-11
EP0941344B1 (en) 2004-05-19
EP0941344A1 (en) 1999-09-15
CA2272842A1 (en) 1998-06-04
ATE267257T1 (de) 2004-06-15
NL300163I1 (nl) 2005-01-03
JP3778945B2 (ja) 2006-05-24
ZA979599B (en) 1999-04-28
WO1998023761A1 (en) 1998-06-04
IL130143A0 (en) 2000-06-01
DK1516629T3 (da) 2013-06-03
IL130143A (en) 2006-08-01
ES2221045T3 (es) 2004-12-16
JP2001505425A (ja) 2001-04-24
CA2272842C (en) 2012-05-15
JP4309383B2 (ja) 2009-08-05
KR20000069147A (ko) 2000-11-25
AU4992997A (en) 1998-06-22
DE69729209T2 (de) 2005-05-19
LU91122I2 (fr) 2005-01-10
PT941344E (pt) 2004-10-29
FR04C0028I2 (https=) 2007-10-26
JP2006036779A (ja) 2006-02-09
AU731817C (en) 2001-11-01
DE122004000047I1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
KR100532178B1 (ko) 인간화 항-ＣＤ11ａ 항체
US6703018B2 (en) Method of treatment using humanized anti-CD11a antibodies
US11485782B2 (en) Anti-claudin 18.2 antibodies
CN101360826B (zh) 抗α2整联蛋白抗体及它们的用途
US20080241126A1 (en) Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAM
KR20010014422A (ko) 개선된 항-ＩｇＥ 항체 및 폴리펩티드의 개선 방법
WO2021047599A1 (en) Humanized anti-claudin 18.2 (cldn18.2) antibodies
JP2001509817A (ja) 抗ｖｅｇｆ抗体
JP2004000249A (ja) 抗体の調製
EP1708961B1 (en) Anti-ip-10 antibodies
EP0946727B1 (en) Antibody mutants
US20040146507A1 (en) Antibody mutants
MXPA99004795A (en) HUMANIZED ANTI-CD11a ANTIBODIES
KR20000075545A (ko) 감마-1 및 감마-3 항사람 ｃｄ23 단클론성 항체 및 치료제로서이들을 사용하는 방법
MXPA99007688A (en) Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021019

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041126

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050601

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20041126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20050627

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20050601

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20050826

Appeal identifier: 2005101004140

Request date: 20050627

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20050627

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20050627

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050426

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20021019

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20050826

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20050728

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081110

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091110

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101122

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111101

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121031

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131030

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131030

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141030

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141030

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150930

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20161028

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20180420

Termination category: Expiration of duration